1. Home
  2. NIC vs AUPH Comparison

NIC vs AUPH Comparison

Compare NIC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nicolet Bankshares Inc.

NIC

Nicolet Bankshares Inc.

HOLD

Current Price

$123.74

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$16.25

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NIC
AUPH
Founded
2000
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
NIC
AUPH
Price
$123.74
$16.25
Analyst Decision
Buy
Buy
Analyst Count
3
4
Target Price
$155.33
$17.25
AVG Volume (30 Days)
126.0K
1.2M
Earning Date
01-20-2026
11-04-2025
Dividend Yield
1.03%
N/A
EPS Growth
18.84
N/A
EPS
9.34
0.55
Revenue
$375,962,000.00
$265,808,000.00
Revenue This Year
N/A
$21.76
Revenue Next Year
$4.72
$16.45
P/E Ratio
$13.23
$29.54
Revenue Growth
9.68
20.62
52 Week Low
$97.90
$6.55
52 Week High
$141.92
$16.54

Technical Indicators

Market Signals
Indicator
NIC
AUPH
Relative Strength Index (RSI) 40.81 63.13
Support Level $129.79 $16.00
Resistance Level $132.84 $16.54
Average True Range (ATR) 3.10 0.41
MACD -0.87 -0.03
Stochastic Oscillator 4.99 80.58

Price Performance

Historical Comparison
NIC
AUPH

About NIC Nicolet Bankshares Inc.

Nicolet Bankshares Inc is a United States-based bank holding company's principal business is banking, consisting of lending and deposit gathering, as well as ancillary banking-related products and services, to businesses and individuals of the communities it serves, and the operational support to deliver, fund and manage. It offers a variety of loans, deposits, and related services to business customers especially small and medium-sized businesses and professional concerns, business deposit products, cash management services, international banking services, business loans, lines of credit, commercial real estate financing, construction loans, agricultural real estate or production loans, and letters of credit, as well as retirement plan services.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: